Alberto Bongiovanni
Overview
Explore the profile of Alberto Bongiovanni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angiulli S, Merolla A, Borgonovo E, De Lorenzo R, Spadoni S, Fontana B, et al.
Front Public Health
. 2025 Feb;
13:1506240.
PMID: 40008147
Background: UNISCREEN is a general population study aiming at evaluating feasibility and acceptability of universal screening for chronic autoimmune (type 1 diabetes and celiac disease) and metabolic/cardiovascular diseases (dysglycemia, type...
2.
Calabrese C, Miserocchi G, De Vita A, Spadazzi C, Cocchi C, Vanni S, et al.
Obes Rev
. 2024 Sep;
25(12):e13833.
PMID: 39289899
The adipose tissue is a complex organ that can play endocrine, metabolic, and immune regulatory roles in cancer. In particular, adipocytes provide metabolic substrates for cancer cell proliferation and produce...
3.
Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D, et al.
J Nucl Med
. 2024 Aug;
65(9):1409-1415.
PMID: 39142827
Recurrence of meningiomas after surgery and radiotherapy deserves specific attention because of the lack of active third-line therapies. Somatostatin receptors are usually overexpressed on the cell membrane of meningiomas, and...
4.
Lagana M, Habra M, Remde H, Almeida M, Cosentini D, Pusceddu S, et al.
Eur J Cancer
. 2024 Jul;
208:114122.
PMID: 39047533
Metastatic pheochromocytomas and paragangliomas (PPGLs) are frequently associated with skeletal complications. Primary objective: to describe the frequency of adverse skeletal related events (SREs) in PPGL patients with bone metastases (BMs)....
5.
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, et al.
Eur J Cancer
. 2024 Jul;
208:114129.
PMID: 39002347
Background: Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies....
6.
Recine F, Vanni S, Bongiovanni A, Fausti V, Mercatali L, Miserocchi G, et al.
Front Immunol
. 2024 Jul;
15:1378398.
PMID: 38983859
Immunotherapy has emerged as promising treatment in sarcomas, but the high variability in terms of histology, clinical behavior and response to treatments determines a particular challenge for its role in...
7.
Panzuto F, Andrini E, Lamberti G, Pusceddu S, Rinzivillo M, Gelsomino F, et al.
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610840
The optimal treatment sequencing for advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) is unknown. We performed a multicenter, retrospective study to evaluate the best treatment sequence in terms of progression-free survival...
8.
Recine F, Bongiovanni A, Mercatali L, Fausti V, Ferraresi V, De Vita A
Front Endocrinol (Lausanne)
. 2023 Dec;
14:1334519.
PMID: 38111704
No abstract available.
9.
Miserocchi G, Bassi M, De Luca G, Calpona S, De Rosa F, Bongiovanni A, et al.
Front Oncol
. 2023 Oct;
13:1245043.
PMID: 37795450
Background: Polymorphous adenocarcinoma (PAC) represents the second most widespread neoplasm of the minor salivary glands. These tumors rarely develop a histological progression from low-grade to high-grade malignancy, named "high-grade transformation"...
10.
Lamberti G, Prinzi N, Bongiovanni A, Torniai M, Andrini E, de Biase D, et al.
Diagnostics (Basel)
. 2023 May;
13(9).
PMID: 37174986
Background: Grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET) are poorly characterized in terms of molecular features and response to treatments. Methods: Patients with G3 GEP-NET were included if they received...